Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 75 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.
- Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular CarcinomaCompletedNCT03033446Phase 2
- Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid TumorsActive, not recruitingNCT03030378Phase 1
- Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung CancerTerminatedNCT03030131Phase 2
- Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube CancerActive, not recruitingNCT03029403Phase 2
- Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal DiseaseActive, not recruitingNCT03025256Phase 1
- Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation LoadsWithdrawnNCT03023904Phase 2
- Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple MyelomaTerminatedNCT03023527Phase 1
- Pulmonary sarcomatoid_MEDI4736+TremeCompletedNCT03022500Phase 2
- Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT03021460Phase 1
- Pembrolizumab for T/NK-cell lymphomasNK-cell LymphomasStatus unknownNCT03021057Phase 2
- Study of Niraparib and TSR-042 in Recurrent Endometrial CancerActive, not recruitingNCT03016338Phase 2
- Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT03015896Phase 1/2
- Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent GlioblastomaWithdrawnNCT03014804Phase 2
- Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic RegimenCompletedNCT03013335Phase 2
- A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative SurgeryTerminatedNCT03013127Phase 2
- Secured Access to Pembrolizumab for Patients With Selected Rare Cancer TypesCompletedNCT03012620Phase 2
- Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer TypesCompletedNCT03012581Phase 2
- Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast CancerCompletedNCT03012230Phase 1
- Study of Adjuvant ONO-4538 With Resected Gastric CancerCompletedNCT03006705Phase 3
- Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced CancersCompletedNCT03005782Phase 1
- Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the LiverCompletedNCT03005002Phase 1
- Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin LymphomaCompletedNCT03004833Phase 2
- MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT03004105Phase 2
- ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck CarcinomaCompletedNCT03003637Phase 1/2
- An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)CompletedNCT03002376Phase 1
- A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid TumorsCompletedNCT03000257Phase 1
- A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ CancerCompletedNCT02999295Phase 1/2
- Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)Active, not recruitingNCT02999087Phase 3
- Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant ExposureCompletedNCT02997995Phase 2
- Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell CarcinomaTerminatedNCT02997332Phase 1
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT StudyActive, not recruitingNCT02997228Phase 3
- Atezolizumab as Induction Therapy in Non-small Cell Lung CancerCompletedNCT02994576Phase 2
- Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral CavityWithdrawnNCT02993991Phase 1
- Pilot Study of Nivolumab in Pediatric Patients With Hypermutant CancersTerminatedNCT02992964Phase 1/2
- Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal CancerTerminatedNCT02991196Phase 1
- Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast CancerTerminatedNCT02990845Phase 1/2
- A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV MelanomaStatus unknownNCT02990416Phase 1/2
- Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic ChordomaActive, not recruitingNCT02989636Phase 1
- A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder CancerActive, not recruitingNCT02989584Phase 1/2
- Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular PatientsCompletedNCT02988440Phase 1
- Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLCTerminatedNCT02987998Phase 1
- Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic MalignanciesTerminatedNCT02985554Phase 1
- Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerActive, not recruitingNCT02983578Phase 2
- Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal CancerTerminatedNCT02982694Phase 2
- A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial CarcinomaStatus unknownNCT02982486Phase 2
- Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin CancersActive, not recruitingNCT02978625Phase 2
- A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced MalignanciesCompletedNCT02978482Phase 1
- Combining Radiosurgery and Nivolumab in the Treatment of Brain MetastasesCompletedNCT02978404Phase 2
- Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast CancerCompletedNCT02977468Phase 1
- Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.CompletedNCT02977156Phase 1
- Optimal Neo-adjuvant Combination Scheme of Ipilimumab and NivolumabActive, not recruitingNCT02977052Phase 2
- Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)CompletedNCT02973113Phase 1
- Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate CancerWithdrawnNCT02966587Phase 2
- Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid TumorsCompletedNCT02966548Phase 1
- Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)WithdrawnNCT02962804Phase 2
- Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal CancerActive, not recruitingNCT02962063Phase 1/2
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney CancerCompletedNCT02960906Phase 2
- Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease ControlTerminatedNCT02959554Phase 2
- CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck CancerActive, not recruitingNCT02955290Phase 1/2
- Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerActive, not recruitingNCT02954874Phase 3
- Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT02950220Phase 1
- Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)WithdrawnNCT02950038Phase 2
- Study to Nivolumab Following Preoperative ChemoradiotherapyStatus unknownNCT02948348Phase 1/2
- Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung CancerCompletedNCT02947386Phase 1
- Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer PatientsCompletedNCT02946671Phase 1
- Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric CancerStatus unknownNCT02942329Phase 1/2
- A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma MacrometastasesCompletedNCT02941744Phase 1/2
- Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin LymphomaActive, not recruitingNCT02940301Phase 2
- Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid TumorsTerminatedNCT02938793Phase 2
- Anti PD-1 Neo-adjuvant Treatment for NSCLCCompletedNCT02938624Phase 1
- Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)CompletedNCT02938273Phase 1
- A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.TerminatedNCT02936102Phase 1
- Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or RelapsedActive, not recruitingNCT02935361Phase 1/2
- Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody AvelumabCompletedNCT02926196Phase 3
- A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare CancersCompletedNCT02923934Phase 2
- Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory NeuroblastomaActive, not recruitingNCT02914405Phase 1
- Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver MetastasesStatus unknownNCT02913417Phase 1/2
- Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid TumorsCompletedNCT02909452Phase 1
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced CancersActive, not recruitingNCT02908906Phase 1/2
- Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaCompletedNCT02902042Phase 1/2
- Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaCompletedNCT02902029Phase 2
- Pembrolizumab, Trastuzumab, HER2 Positive Gastric CancerStatus unknownNCT02901301Phase 1/2
- Nivolumab in Relapsed Pediatric Solid TumorsStatus unknownNCT02901145Phase 1/2
- A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)CompletedNCT02900664Phase 1
- A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder CancerCompletedNCT02897765Phase 1
- A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)CompletedNCT02892318Phase 1
- ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+BevacizumabCompletedNCT02891824Phase 3
- Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis FungoidesTerminatedNCT02890368Phase 1
- A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatCompletedNCT02890069Phase 1
- Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)WithdrawnNCT02885727Phase 2
- Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the SkinCompletedNCT02883556Phase 2
- Preoperative Administration of Olaparib With Cisplatin or With Durvalumab or Alone or no Tratment in Patients Who Are Candidates for Surgery of Carcinoma of the Head and Neck.CompletedNCT02882308Phase 2
- RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 MonotherapyWithdrawnNCT02880345Phase 1
- Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by SurgeryCompletedNCT02880020Phase 2
- Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer PatientsCompletedNCT02879760Phase 1/2
- Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other TumorsCompletedNCT02876224Phase 1
- BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic MelanomaCompletedNCT02872259Phase 1/2
- Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)Active, not recruitingNCT02872025Early Phase 1
- Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia MyelofibrosisWithdrawnNCT02871323Phase 1
- Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic CancerWithdrawnNCT02868632Phase 1